Business Context and Reporting Period
This Form 8-K is a current report filed by Pluristem Therapeutics Inc. (also referred to as Pluri Inc.) on December 13, 2010, regarding an event that occurred on December 12, 2010. The company is incorporated in Nevada and maintains its principal executive offices in Haifa, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
The primary material change reported is the approval by the Tel-Aviv Stock Exchange (TASE) for the listing of the registrant's common stock. Trading on the TASE is scheduled to commence on December 19, 2010, under the ticker symbol PLTR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific event of the stock exchange listing approval.
Investor Verification Checklist
- Confirm the commencement of trading on the Tel-Aviv Stock Exchange on December 19, 2010.
- Verify the ticker symbol PLTR on the TASE.
- Review subsequent filings for financial data, as this 8-K contains no financial statements.